Optimal Industrial Automation will be joined by process analytical technology (PAT) luminaries in Wicklow, Ireland this February as the company showcases the efficiency gains made using its revolutionary synTQ V5 software.
'Adoption of Continuous Manufacturing in the Pharmaceutical Industry' will take place from the 22nd – 23rd February at the Druids Glen Hotel, and will gather specialists from major manufacturers, academia and regulatory bodies to discuss advancements and implementation paths for the technology.
Optimal will be showcasing its synTQ V5 software over the duration of the exhibition. synTQ is a proven PAT platform software suite that enables continuous manufacturing as well as delivering other important benefits such as improved quality and holistic manufacturing over multiple sites. It has already been implemented by a number of major pharmaceutical manufacturers in product development and production applications to enable regulatory compliant real-time closed loop control of drug manufacture.
The result is continuous pharmaceutical production that can be automatically controlled and optimised to achieve a finished product that displays improved quality attributes and at the same time meets regulatory standards. This new way of processing changes the requirement to test product in static batches mid-process and post production; which can greatly extend the manufacturing time for drugs; to real time automated quality testing with the possibility of Real time Release. Therefore, the principle benefit of the technology is that it can reduce the time to market for pharmaceuticals drastically. For some drugs this means from weeks to minutes, with a commensurate reduction in costs and increase in production capacity, from the same footprint.
Institutions represented at the exhibition include the U.S. Food and Drug Administration (FDA), Eli Lilly and Company, Amgen, Sanofi, University College Cork, Dublin and Purdue University. All attendees will gather to engage in various discussions and workshops to share experiences with PAT, and define what the future holds for the technology. With uptake of the framework technology growing year on year, PAT is now enabling a paradigm shift in the pharmaceutical manufacturing sector and its production processes.
Martin Gadsby, Director of Optimal Industrial Automation, comments: "With a revolutionary new technology such as synTQ for PAT, the need for discussion between users, regulators and academia is paramount to ensure smooth integration into manufacturing and development processes. No implementation path is the same, as each product has its own manufacturing (and PAT) requirements. However, using platforms like synTQ, we can unify necessary information to enable control of processes like never before. We are committed to the further development of synTQ, and are honoured to be considered amongst the pioneers of realising the theory and making the technology work."
Adoption of Continuous Manufacturing in the Pharmaceutical Industry takes place from 22nd – 23rd February 2017 at the Druids Glen Hotel, Newtown Mount Kennedy, Co. Wicklow, Ireland.
You can learn more about the event here, or to discover more about synTQ, visit the website.